Oyster Point Pharma, Inc.
DelistedCIK 1720725fmd_0HCTF4T6AGS2VKF5R7E7DR966HManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2022, 19 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|
| Total revenues | – | – | 0 | 25 |
| Cost of revenue | – | – | 0 | 2 |
| Gross profit | – | – | 0 | 23 |
| Research and development | 14 | 34 | 40 | 24 |
| Selling, general and administrative | – | – | 31 | 95 |
| Total operating expenses | 17 | 47 | 71 | 120 |
| Operating income | (17) | (47) | (71) | (97) |
| Interest expense | – | – | 0 | 4 |
| Interest and investment income | 0 | 2 | 0 | – |
| Other non-operating income (expense) | – | – | 0 | (4) |
| Income before taxes | (17) | (46) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (17) | (46) | – | – |
| Net income | (17) | (46) | (71) | (101) |